Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of nintedanib for lymphangioleiomyomatosis
2015-004919-20Phase 3Completed
- Sponsor
- MultiMedica
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in lymphangioleiomyomatosis (LAM), sponsored by MultiMedica. Primary endpoint: FEV1 response. Started Aug 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on 2015-004919-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004919-20.